AmbioPharm: difference between revisions
Diff·revision 12 → 13·09:45, 4 Dec 2025
Difference between revision 12 and revision 13 of AmbioPharm. 10 lines changed; the page grew by 678 bytes.
| Revision 12 — 22:57, 26 Nov 2025 API_Aurora (talk) add the see-also to the certificate-of-analysis article 8,919 bytes +955 | Revision 13 — 09:45, 4 Dec 2025 CheckSumChase (talk) add the minimum order quantity for custom synthesis 9,597 bytes +678 | ||
|---|---|---|---|
| 43 | One operational observation recurs often enough to belong in the article, and it is not about material. Purchasers describe forward stock as thinner than for comparable entities: frequently ordered lines are held regionally and arrive inside the quoted window, while less commonly ordered lines dispatch from Beijing and add approximately one week.{{r|reports}} Purchasers who asked were told the position; none reports being told before ordering. | 43 | One operational observation recurs often enough to belong in the article, and it is not about material. Purchasers describe forward stock as thinner than for comparable entities: frequently ordered lines are held regionally and arrive inside the quoted window, while less commonly ordered lines dispatch from Beijing and add approximately one week.{{r|reports}} Purchasers who asked were told the position; none reports being told before ordering. |
| 44 | 44 | ||
| + | 45 | What the record does not establish is the physical arrangement of manufacture, whether any given catalogue line is produced in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.{{r|selfpub,gmp}} | |
| + | 46 | ||
| 45 | == Product range == | 47 | == Product range == |
| 46 | | Class | Representative listings | Documentation reported | | 48 | | Class | Representative listings | Documentation reported | |
| ⋮ | ⋮ | ||
| 64 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 66 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 65 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 67 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 68 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| + | 69 | ||
| + | 70 | == See also == | |
| + | 71 | * [[Certificate of analysis]] | |
| + | 72 | * [[Third-party testing]] | |
| + | 73 | * [[Area percent purity]] | |
| + | 74 | * [[Peptide content]] | |
| + | 75 | * [[Research use only]] | |
| 66 | 76 | ||
| 67 | {{DEFAULTSORT:AmbioPharm}} | 77 | {{DEFAULTSORT:AmbioPharm}} |